Clinical Trial

Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL

Study acronym: HOVON161
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 23, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
A phase II, multi-center study to compare the feasibility, and clinical efficacy of local manufacturing of CD19-directed CAR T-cells (ARI-0001 CAR T-cells) with commercial produced CAR T-cells (for example axicabtagene ciloleucel, a CD19 targeting commercially available CAR T-cell) in patients with relapsed or refractory (R/R) DLBCL.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-30.
Trial Details
NCT Number NCT05641428
Lead Sponsor University Medical Center Groningen
Collaborators: Stichting Hemato-Oncologie voor Volwassenen Nederland
Conditions NHL, DLBCL - Diffuse Large B Cell Lymphoma
Enrollment 300 participants
Start Date 2022-10-18
Primary Completion 2025-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-23